Doxycycline for STDs Prevention
(foXXxy doxy Trial)
Trial Summary
What is the purpose of this trial?
The goal of this open-label, randomized trial is to assess the efficacy of doxycycline prophylaxis in reducing incidences of bacterial sexually transmitted infections (STIs) among adolescent and young adult females while also evaluating acceptability and antimicrobial resistance in order to inform public health policy.
Research Team
Cherie Blaire, MD, PhD
Principal Investigator
University of California, Los Angeles
Jenell Stewart, DO, MPH
Principal Investigator
Hennepin Healthcare
Eligibility Criteria
This trial is for individuals assigned female at birth who are seeking to prevent bacterial sexually transmitted infections (STIs). Participants must be willing to take doxycycline weekly and be monitored for the development of antimicrobial resistance.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomized to receive on-demand doxycycline post-exposure prophylaxis, weekly doxycycline, or standard of care, with quarterly STI testing and sexual health counseling
Follow-up
Participants are monitored for safety and effectiveness after treatment, including STI testing and resistance testing
Treatment Details
Interventions
- Doxycycline
Doxycycline is already approved in United States, European Union, Canada, Japan for the following indications:
- Acne
- Bacterial infections
- Chlamydia
- Gonorrhea
- Lyme disease
- Malaria
- Pneumonia
- Rosacea
- Urinary tract infections
- Acne
- Bacterial infections
- Chlamydia
- Gonorrhea
- Lyme disease
- Malaria
- Pneumonia
- Rosacea
- Urinary tract infections
- Acne
- Bacterial infections
- Chlamydia
- Gonorrhea
- Lyme disease
- Malaria
- Pneumonia
- Rosacea
- Urinary tract infections
- Acne
- Bacterial infections
- Chlamydia
- Gonorrhea
- Lyme disease
- Malaria
- Pneumonia
- Rosacea
- Urinary tract infections
Find a Clinic Near You
Who Is Running the Clinical Trial?
Westat
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)/Division of AIDS (DAIDS)
Collaborator
National Institute on Drug Abuse (NIDA)
Collaborator
National Institute of Mental Health (NIMH)
Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator
National Institutes of Health (NIH)
Collaborator
Florida State University
Collaborator